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clinical presentation and broad histopathological spectrum 
of these highly epileptogenic brain tumors will herein be 
classified as “long-term epilepsy associated tumors—
LeATs”. LeATs differ from most other brain tumors by 
early onset of spontaneous seizures, and conceptually are 
regarded as developmental tumors to explain their pleomor-
phic microscopic appearance and frequent association with 
Focal Cortical Dysplasia Type IIIb. However, the broad 
neuropathologic spectrum and lack of reliable histopatho-
logical signatures make these tumors difficult to classify 
using the wHO system of brain tumors. As another con-
sequence from poor agreement in published LeAT series, 
molecular diagnostic data remain ambiguous. Availabil-
ity of surgical tissue specimens from patients which have 
been well characterized during their presurgical evaluation 
should open the possibility to systematically address the 
origin and epileptogenicity of LeATs, and will be further 
discussed herein. As a conclusion, the authors propose a 
novel A–B–C terminology of epileptogenic brain tumors 
(“epileptomas”) which hopefully promote the discussion 
between neuropathologists, neurooncologists and epilep-
tologists. It must be our future mission to achieve interna-
tional consensus for the clinico-pathological classification 
of LeATs that would also involve world Health Organiza-
tion (wHO) and the International League against epilepsy 
(ILAe).
Long‑term epilepsy‑associated brain tumors (LEATs): 
what’s old, new, and blue?
virtually any brain tumor can cause seizures. This review 
will focus on a particular group of brain tumors that usu-
ally manifest with seizure onset during early life (mean 
age = 16.5 years; Table 1), and which present with a broad 
Abstract every fourth patient submitted to epilepsy sur-
gery suffers from a brain tumor. Microscopically, these 
neoplasms present with a wide-ranging spectrum of glial 
or glio-neuronal tumor subtypes. Gangliogliomas (GG) and 
dysembryoplastic neuroepithelial tumors (DNTs) are the 
most frequently recognized entities accounting for 65 % 
of 1,551 tumors collected at the european epilepsy Brain 
Bank (n = 5,842 epilepsy surgery samples). These tumors 
often present with early seizure onset at a mean age of 
16.5 years, with 77 % of neoplasms affecting the tempo-
ral lobe. Relapse and malignant progression are rare events 
in this particular group of brain tumors. Surgical resection 
should be regarded, therefore, also as important treatment 
strategy to prevent epilepsy progression as well as seizure- 
and medication-related comorbidities. The characteristic 
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histopathological spectrum of low-grade glial and glio-neu-
ronal phenotypes [12, 42, 64, 66, 88, 94]. Herein, we des-
ignate this group as long-term epilepsy-associated brain 
tumors (LeATs or epileptomas). As in any other patient with 
a brain tumor, LeATs are readily detectable with standard-
ized neuroimaging techniques (Figs. 1, 2). In contrast to 
Table 1  Neuropathological findings in epilepsy surgery
Data retrieved from the european epilepsy Brain Bank
HS hippocampal sclerosis, Dual dual pathology, LEAT long-term epilepsy-associated tumors, MCD malformations of cortical development, Age 
OP age of patients at surgery (in years), Onset age at onset of spontaneous seizure activity (in years), Duration duration of seizure disorder 
before surgical treatment (in years)
Category Numbers (%) Age OP Onset Duration
HS 1,908 (32.7 %) 33.9 + 10.4 11.3 + 7.7 22.7 + 10.0
Dual 294 (5.0 %) 25.5 + 12.8 9.5 + 7.8 15.9 + 9.9
LeAT 1,551 (26.5 %) 27.9 + 12.3 16.5 + 10.1 11.8 + 8.8
MCD 930 (15.9 %) 18.2 + 12.0 5.9 + 5.7 12.3 + 9.1
vascular 328 (5.6 %) 36.1 + 12.3 23.4 + 11.4 12.7 + 9.0
Glial scars 284 (4.9 %) 25.6 + 12.4 10.3 + 8.0 14.7 + 8.6
encephalitis 96 (1.6 %) 20.4 + 12.6 13.3 + 9.4 8.2 + 7.1
No lesion 451 (7.7 %) 29.2 + 10.8 12.6 + 7.7 16.1 + 8.0
Total 5,842 28.6 + 12.5 12.4 + 8.9 16.5 + 10.1
Fig. 1  MRI characteristics of LeAT (CD34-positive BNeT). a–g 
6-year-old boy with drug-resistant temporal lobe epilepsy. Coronal 
T2-weighted (a, b), sagittal T2-weighted (c), coronal FLAIR (d), and 
coronal T1-weighted contrast-enhanced images (e) show a cortical/
subcortical tumor with a cortical cyst (a, c: arrow), a contrast-enhanc-
ing nodule (arrow in e), and a T2-/FLAIR hyperintense white matter 
portion (a, f, g: arrowhead). Histopathological diagnosis was CD34-
positive ganglioglioma (BNeT)
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most gliomas, slow LeAT growth and low risk for malignant 
progression may not necessitate immediate surgical interven-
tion, nor will surgical strategies help to achieve long-term 
seizure control when aiming only at gross tumor resection. 
A common goal for successful treatment of these patients is 
the accurate identification of the epileptogenic zone, which 
Fig. 2  MRI characteristics of LeAT (DNeT, ANeT and INeT). 
a–d 36-year-old man with temporal lobe seizures and histopathologi-
cal diagnosis of DNeT in the left amygdala and hippocampal head. 
The tumor revealed multiple tiny cysts, which can be resolved only 
by high-resolution T2-weighted (a, c: arrow), but not on FLAIR 
images (b, d). Axial T1-weighted (e), sagittal FLAIR (f), and axial 
T2-weighted images (g) showed a circumscript cortical and subcorti-
cal tumor at the base of the left parietal lobe dorsal to the cingulate 
gyrus. A ribbon-like cortical T1-hyperintensity (arrow in e) can be 
identified, and histopathology confirmed an ANeT. h–k Isomorphic 
variant of astrocytoma (INeT). The hippocampal and parahippocam-
pal lesion has a space-occupying effect and a homogenous signal 
increase on T2 (h: arrow) and signal decrease on T1-weighted images 
(i: arrow), respectively. Signal changes suggested low cellularity with 
no contrast enhancement (k)
42 Acta Neuropathol (2014) 128:39–54
1 3
may or may not match with the MRI visible lesion [31]. 
Advanced neurophysiological procedures including invasive 
eeG recordings may be needed in some patients [36, 43, 
77], as discussed further below. However, weak agreement 
in the histopathological diagnosis of LeAT tumor entities 
[88] challenges any meaningful interpretation of published 
patient series. A major reason for poor agreement is the 
large spectrum of morphological variants when reviewing 
routinely stained hematoxylin and eosin (He) sections, shar-
ing one or more of the following features: (1) LeATs have 
a histologically variable appearance consisting of dysplas-
tic neuronal and neoplastically transformed glial elements, 
mostly classified as glio-neuronal tumors by the world 
Health Organization (wHO) [42, 50]. (2) The vast major-
ity of LeATs correspond to wHO Grade I [52, 53]. Reliable 
guidelines for the identification of tumors that carry a higher 
risk for recurrence and malignant progression are not avail-
able [12, 50]. (3) LeATs occur predominately in the tempo-
ral lobe and present with early seizure onset (with a mean 
age at seizure onset = 16.5 years). However, the average 
duration of epilepsy before surgical treatment adds another 
12 years in our series of 1,551 patients (Table 1; Fig. 3b). 
(4) LeATs are likely to occur during brain development [8]. 
As such, tumors can be associated with Focal Cortical Dys-
plasia (FCD ILAe Type IIIb) [11, 58], or small tumor satel-
lites infiltrating the adjacent neocortex (see chapters below). 
which tumor entity preferentially follows which of these 
peculiar patterns, and whether any of these features con-
tribute to enhanced epileptogenicity are important and yet 
unanswered questions in need of clarification. (5) LeATs do 
not share molecular features typically observed in diffusely 
infiltrating gliomas, such as IDH1 mutations or 1p/19q dele-
tions [3, 57, 60, 95]. In contrast, the oncofetal marker protein 
CD34 can be frequently identified [7] and developmental 
genes are likely to be involved [40]. Mutations in B-RAF 
[45] or mammalian target of rapamycin (mTOR) signaling 
[5] have been also identified as key features in this group of 
tumors (see chapters below).
Fig. 3  LeAT submission to the european epilepsy Brain Bank 
(eeBB) in last 20 years. a During the last 20 years, submission fre-
quencies have decreased for HS and increased for MCD (75 % 
FCD), whereas percentages of brain tumors associated with early 
epilepsy onset (LeAT) remained consistent over time. b Disease 
duration (time period from seizure onset until surgery; sz—seizures) 
has remained unchanged in HS and MCD during the last 20 years, 
whereas today’s patients with LeAT were operated 5 years earlier 
compared to mid 1990s (mean of 7.4 vs 12.9 years, respectively). 
eeBB submissions were grouped into four clusters of 5-year intervals 
between 1994 and 2013 to observe changes over time
Table 2  Neuropathological spectrum of brain tumors in an european 
epilepsy surgery series
Summary of 1,551 LeAT diagnosis collected by the eeBB (total 
n = 5,842); 709 female and 821 male patients were included. Grad-
ing according to wHO I°, II° or III° [50]
Age at operation (mean in years); Age at epilepsy onset (mean in 
years); epilepsy duration (mean in years)
GG gangliogliomas, DNET dysembryoplastic neuroepithelial tumors, 
PXA pleomorphic xantoastrocytomas, INET isomorphic astrocytoma 
variants (analogous to wHO I°; [9, 10, 80]), SEGA subependymal 
giant cell astrocytomas, ANET angiocentric gliomas, ASTRO astrocy-
toma variants, OLIGO oligodendrogliomas including mixed gliomas, 
PA pilocytic astrocytomas, CYSTS arachnoid, dermoid or epidermoid 
cysts, NOS highly differentiated neuroepithelial tumors (not other-
wise specified), Other all other tumors at rare frequency (<1 %)
entity Numbers (%) Age OP Onset Duration
GG I° 673 (43.3 %) 24.9 12.8 12.7
GG II°/III° 77 (5.0 %) 26.9 14.2 11.0
DNeT I° 256 (16.5 %) 25.2 14.7 10.7
PXA 38 (2.5 %) 29.3 18.8 12.2
INeT 29 (1.9 %) 27.9 14.4 17.7
SeGA 16 (1.0 %) 20.1 12.3 9.0
ANeT 5 (0.3 %) 19.7 2.0 13.0
ASTRO II°/III° 110 (7.1 %) 36.2 29.5 6.7
OLIGO II°/III° 97 (6.3 %) 38.6 24.5 12.5
PA I° 81 (5.2 %) 25.1 14.8 12.1
CYSTS 31 (2.0 %) 32.4 21.7 11.6
MeNINGIOMA 26 (1.7 %) 46.5 38.9 8.4
NOS$ 62 (3.2 %) 29.2 16.1 13.3
OTHeR§ 50 (4.0 %) 31.5 25.0 11.3
Total 1,551 27.9 16.5 11.7
43Acta Neuropathol (2014) 128:39–54 
1 3
It is difficult to microscopically describe and histopatho-
logically classify the broad spectrum of LeAT entities and 
their variants (Table 2) using standard eosin and hematoxy-
lin (H&e) stains, which produce different histomorpho-
logical classification schemes of LeAT subtypes, i.e., the 
four different variants of a dysembryoplastic neuroepithe-
lial tumor (DNT) with diffuse and simple forms, as well as 
complex and non-specific variants [13, 41, 89]. Other strat-
egies have tried to incorporate rare or unusual subtypes into 
well-introduced wHO tumor entities, such as the GG [12]. 
As a matter of fact, meta-analysis of any published LeAT 
series is almost impossible and generates inconsistent 
results, despite adhering to the existing wHO classification 
system for brain tumors. In a previous review of eight inter-
national LeAT series (covering a total of 2,055 patients), 
we identified DNT and GG as the most prevalent entities 
[88]. However, the reported percentages for both categories 
showed a huge variance between published patient cohorts 
ranging from 7 to 70 %. These figures suggested a geo-
graphical bias, by which same tumors were classified either 
as GG or DNT, reflecting differences in neuropathology 
schools rather than reliable histopathological signatures. 
Again, the controversial and enigmatic question whether 
malignant progression can occur in a DNT (comprising 
any of its described variants) is a good, albeit unpleasant, 
example [21, 72].
Increasing availability of surgical tumor specimens 
should open the possibility to better characterize the 
molecular signature of each LeAT variant along with their 
molecular pathogenesis and epileptogenic potential. Not-
withstanding, such studies will require use of a reliable ter-
minology and histopathological classification that can be 
reproduced by any other laboratory. Prospectively designed 
randomized controlled trials for LeAT treatment are nec-
essary to provide class 1 evidence for any suggested bio-
marker and classification scheme, an important goal that 
has never been addressed or realized up to this day.
Epidemiological findings and neuropathological 
classification of LEATs: a matter of ongoing debate
The benefit of tailored resection strategies in patients with 
drug-resistant temporal lobe epilepsy is also recognized 
for the treatment of LeAT patients [52, 53, 86]. The com-
prehensive database of the european epilepsy Brain Bank 
(eeBB) currently includes 5,842 samples, of which one 
quarter is diagnosed as LeAT (Table 1). with mean epi-
lepsy duration of 11.8 years (Table 1), many tumors appear 
to escape detection in patients with early seizure onset 
or are medically treated for a long period of time period 
before surgery is considered as “ultima ratio”. Due to the 
preferential localization of LeATs in the temporal lobe, the 
various consequences of long-term epilepsy on cognition 
as well as social development and behavior require care-
ful consideration [35] and seem to have already shifted the 
attitude of many epileptologists, neurologists and neurosur-
geons toward earlier surgical intervention (Fig. 3b).
Neuropathological examination and diagnosis rely on 
microscopical inspection of surgical brain specimens and 
follow the current wHO classification and grading scale 
(last revised in 2007) [50]. This classification scheme has 
proven useful for the prediction of the biological behav-
ior of most gliomas and other CNS tumor entities [51]. 
However, the broad spectrum of LeATs and their variable 
histomorphological features are not fully reflected within 
the current wHO grading system. Our eeBB collection of 
1,551 LeAT cases included more than 15 different tumor 
entities in 709 female and 821 male patients (Table 2). 
Consequently, it is important to emphasize that proper neu-
ropathological evaluation should be obtained from experi-
enced centers. The need for such expertise is mandatory, 
given the considerable variability of histopathological 
phenotypes, which might result in “over-interpretation” of 
tumor progression leading to erroneous use of more aggres-
sive therapeutic measures, even though most LeATs tend 
to have a very modest clinical behavior in the long run 
without bold risk of recurrence or malignant transforma-
tion [53]. At the same time, some tumors with a histologi-
cally typical, “benign”, glio-neuronal phenotype have been 
reported to rapidly turn into malignancies [54], underscor-
ing the need for reliable biomarkers that could be used to 
predict the biological behavior of each individual tumor.
Lack of diagnostic agreement requires new concepts: 
proposal of the A–B–C terminology of epileptomas
Given the broad histopathological spectrum of LeATs and 
the contradictory results published in the literature [88], 
we need to pursue better definitions and use standardized 
parameters for the neuropathological diagnosis of tumors 
associated with early onset epilepsy (epileptomas). Such 
a proposal would also help reinforce research strategies 
toward a better understanding of the underlying biological 
nature (i.e., molecular pathogenesis), risk of malignant pro-
gression (i.e., predictive biomarkers), their epileptogenic 
potential (including presence or absence of FCD), and 
would allow for meaningful comparisons among published 
research studies and clinical patient series (i.e., epidemio-
logical measures). Notwithstanding, there are no prospec-
tive, randomized, controlled trials of LeATs inpatients with 
epilepsy that demonstrate any better interrater agreement 
and superior predictive value of an alternative classification 
scheme. On the other hand, neuropathologists have already 
gone through these long and controversial discussions and 
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disagreements 20 years ago with regard to the classifica-
tion of malignant gliomas or medulloblastomas. As a result, 
the neuropathology community has now attained major 
achievements in specifying useful molecular diagnostic 
approaches and targeted therapies in these brain tumors 
[33, 34, 38, 81, 83, 87]. It seems that we are 20 years 
behind, when it comes to LeATs and associated epilepsies, 
and urgently need to shift our attention toward developing 
and implementing a new, clinically applicable consensus 
terminology for the neuropathological diagnosis of LeAT.
Fig. 4  The spectrum of histomorphological and immunohistochemi-
cal hallmarks in LeATs with a glio-neuronal phenotype (A–B–C 
terminology). a BNeT, immunoreactive for CD34 class II epitope 
(mAB QBend10, hematoxylin counterstaining; first three columns). 
Three different patterns can be distinguished. Pattern 1: (TU)—the 
bulk tumor is densely stained for CD34 (magnification in f). Pattern 
2: clusters of tumor cells are visible in adjacent cortical areas (arrow, 
magnification in g). Pattern 3: diffusely infiltrating CD34-positive 
cells can be found in distant remote areas from the bulk tumor (mag-
nification in h). Note, that patterns 2 and 3 may be interpreted as 
FCD ILAe Type IIIb when not using CD34 immunohistochemistry. 
b, c Routine histology stainings (H&e) reveal a biphasic pattern in 
BNeT and a predominant gangliocytic patter in GNeT. d, e Immuno-
histochemistry for the embryonic MAP2 epitope (MAP2e) is helpful 
to identify the neuronal component. Compared to diffusely infiltrating 
gliomas, the glial component does not label for Map2e (see Figs. 5, 
6). i no CD34 immunoreactivity is visible in GNeTs. k–n Sup-
plementary markers are helpful to distinguish LeAT entities. NeuN 
labels dysplastic neurons in BNeTs (k). IDH1 staining is always 
recommended as it is detectable only in neoplastically transformed 
glial cells (diffuse astrocytomas AII and oligodendroglioma OII; see 
Figs. 5, 6), but not in BNeT (l). Synaptophysin (SYN) may be help-
ful to visualize the neuronal component in BNeT (m) and GNeT (n). 
Scale bar in a 2 mm, d 50 µm applies also to b, c, e, i–n. Scale bar in 
g 200 µm, applies also to f–h
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Given that the spectrum of histopathological changes of 
most glio-neuronal tumors is highly variable and cannot 
be sufficiently characterized by H&e staining alone, we 
recommend the introduction and routine use of a selected 
panel of immunohistochemical stainings that would allow 
neuropathologists to generate an appropriate differential 
diagnosis of LeATs as well as their distinction from other 
gliomas, i.e., CD34 [7, 8, 28, 61] and MAP2 [6, 10, 12, 
76, 84] (Figs. 4, 5, 6). According to published experience 
with these immunohistochemical markers [53], we pro-
pose a terminology, which would allow us to classify the 
majority of tumors that fall under the entire LeAT spec-
trum. As an example, the frequently used term “Gangli-
oglioma” could be replaced by two new terms based on the 
Fig. 5  The spectrum of histomorphological and immunohistochemi-
cal hallmarks in LeATs with an astrocytic phenotype (A–B–C ter-
minology). a–c Routine histology stainings reveal an angiocentric 
pattern in ANeT (first column), or a prevailing astrocytic differentia-
tion in INeT (second column; similar to diffuse astrocytoma (AII; 
third column) shown in c). d He staining from normal white matter 
(control/CTR) obtained from epilepsy surgery specimens; forth col-
umn. e–h Immunohistochemistry for the embryonic MAP2 epitope 
(MAP2e) is helpful to separate diffuse gliomas (AII, g) variants from 
any other LeAT entity (see also Figs. 4, 6). Only preexisting neurons 
and neuronal processes are visible in INeT (f), comparable with het-
erotopic white matter neurons frequently seen in epilepsy surgery 
samples (h). Map2e-labeled cells in ANeT (e) support the concept 
of a neuroepithelial tumor. i–l None of these variants shows CD34 
immunoreactivity compared to BNeT (see Fig. 4). m MAP2e stain-
ing in normal neocortex (layer 3; same specimen than d, h, and r). 
n–r Supplementary markers are helpful to distinguish LeAT entities. 
eMA dots can be frequently encountered in ANeT variants. IDH1 
staining is recommended to exclude neoplastically transformed glial 
cells in diffuse astrocytomas (p; see also Fig. 6), but not in INeT (o). 
Scale bar in b 50 µm, applies to all images, with the exception of (n) 
20 µm
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presence or absence of the CD34 oncofetal class II epitope 
[7, 8, 28, 61]. The proposed terms are: basic (oncofetal) 
neuroepithelial tumor “BNeT” with CD34 expression, 
compared to a (predominant) gangliocytic neuroepithelial 
tumor “GNeT” without CD34 expression (Fig. 4). This 
new terminology would likely help avoid the confusion that 
characterizes previous reports, and which have included a 
broad histopathological spectrum of gangliogliomas and 
DNTs associated with various degrees of gangliocytic 
components [13, 66, 84, 88, 89]. BNeTs will always be 
devoid of MAP2 labeling within their glial cell component 
(Fig. 4; Table 3). The MAP2 epitope of interest is an alter-
natively spliced transient (embryonic) isoform including 
exon 13 (MAP2e) [6, 82]. This isoform is likely to occur 
also in astroglial precursors [6] and can be detected in the 
vast majority of diffusely infiltrating gliomas [10, 76]. we 
Fig. 6  The spectrum of histomorphological and immunohistochemi-
cal hallmarks in LeATs with a clear cell morphology (A–B–C ter-
minology). a–c Routine histology stainings reveal the specific glio- 
neuronal element in DNeT (a, b; first and second columns), which 
may be difficult to distinguish from some oligodendroglioma variants 
(OII; third and forth columns). d OII infiltrating diffusely into neocor-
tex (also in h, m, r). e–h Immunohistochemistry for the embryonic 
MAP2 epitope (MAP2e) is variable in DNeT variants with abundant 
labeling of glial and neuronal cells (e) or neurons only (f). Neoplasti-
cally transformed glial cells always label with MAP2e in OII (g, h). 
i–m CD34 immunoreactivity is always devoid in DNeTs as well as 
clear cell glioma variants. Immunoreactivity of vascular endothe-
lium can be used as positive control. n–r Supplementary markers are 
helpful to distinguish LeAT entities. IDH1 staining is always recom-
mended as it is detectable only in neoplastically transformed glial cells 
(oligodendroglioma OII, p–r), but not in DNeT (n). NeuN may be 
helpful to visualize the neuronal component in DNeTs (o). Scale bar 
in a 50 µm, applies to images b, c, e, f, g, i, k, l, n, o, p. Scale bar in 
d 20 µm, applies also to h, m and r
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consider this as important evidence for excluding any semi-
malignant tumor mimicking LeAT variants, i.e., if only 
fragmented surgical specimens are available for diagnos-
tic review and evidence for entrapped preexisting neuronal 
subpopulations is difficult to obtain. Mutation-specific anti-
bodies directed against the IDH1 enzyme are important 
markers highly recognized in diffuse gliomas [3, 18, 19, 
37, 60], and should be also encountered in the histopatho-
logic LeAT work-up panel to identify and differentiate dif-
fuse glioma variants.
The microscopic appearance of BNeTs shares the broad 
spectrum of gangliogliomas described in the literature with 
dysplastic neuronal and neoplastically transformed glial 
components (Fig. 4) [5, 12]. BNeTs will frequently reveal 
calcification, lymphocytic infiltrates and protein droplets. 
The dysplastic neuronal component may be difficult to 
identify when searching for multinucleated neurons, which 
requires additional immunohistochemical measures, i.e., 
synatophysin [29], NeuN [93] or MAP2 [10]. Few BNeT 
variants can thereby present with a predominant glial cell 
population (astroglial or with clear cell morphology), 
which need to be distinguished from diffusely infiltrat-
ing astrocytomas or oligodendrogliomas using appropriate 
immunohistochemical markers, such as IDH1 and MAP2 
[10, 18].
The growth pattern of BNeTs may be nodular but dif-
fuse infiltration into adjacent neocortex and white matter is 
also frequently encountered. This growth pattern becomes 
even more evident using CD34 immunohistochemistry, as 
the class II CD34 epitope is not expressed in the adult nor-
mal mammalian central nervous system or any other neu-
roimmunological or neurodegenerative disease. In BNeTs, 
CD34 immunolabeling presents with three common pat-
terns (Fig. 4). Type I labels bulk tumor cells (Fig. 4e), Type 
II diffusely infiltrating tumor cells (Fig. 4h) and Type III 
what we called “tumor satellites”. These are small clusters 
or nodules of CD34 immunoreactive cells in remote corti-
cal areas. These may not be detectable by H&e staining, 
and often cause misinterpretation as FCD Type IIIb [11]. 
Such satellites can be immunohistochemically identified 
even if small or fragmented surgical specimens are avail-
able for histopathological review. However, described pat-
terns for CD34 immunoreactivity may not be simultane-
ously present in each tumor specimen. Some BNeT will 
reveal all three patterns, which usually require an anatomi-
cally well-preserved surgical specimen. On the other hand, 
BNeTs may only show Type II or III patterns, in particular 
if fragmented specimens are available. However, their pres-
ence is sufficient to classify them as BNeT. So far, no other 
disease condition or normal brain cell population has been 
shown to express the class II CD34 epitope. Unfortunately, 
the nature and origin of CD34 immunoreactive cells have 
not been clarified in BNeTs, but most likely present neo-
plastically transformed neural precursor cells [7], although 
normal precursor cells or any other normal adult cell popu-
lation in the human brain were never shown to express the 
CD34 class II epitope [7].
A challenge for the differential diagnosis is to distin-
guish BNeTs from other brain tumors expressing CD34, 
such as pleomorphic xanthoastrocytomas [73]. BNeTs may 
also share cytological features of pilocytic astrocytomas 
and oligodendrogliomas, which need careful consideration 
(Figs. 4, 5). Immunohistochemical stainings using IDH1 
and MAP2 will help to clarify their differential diagnoses 
[10].
The term “DNeT” and its current wHO definition will 
remain unchanged in this proposal. As originally described 
by Daumas-Duport, DNeTs exhibit the characteristic mul-
tinodular appearance and specific glio-neuronal element 
Table 3  Terminology proposal for long-term epilepsy-associated 
tumors
CD34 (class II epitope) labels non-endothelial (oncofetal) cells [7]. 
MAP2 refers to the embryonic MAP2e isoform including exon13, 
which can be detected in neoplastically transformed glial cells [6, 
85], in contrast to neurons that express the matured high-molecular 
weight MAP2
Astrocytomas and Oligodendrogliomas should always be excluded 
by testing for IDH1 mutations (as well as 1p/19q losses), which 
are considered as the most significant discriminators between 
astrocytomas/oligodendrogliomas and A–B–C LeATs. Pilocytic 
astrocytomas, pleomorphic xanthoastrocytomas, subependymal 
giant cell astrocytomas, papillary glio-neuronal tumors, or rosetted 
glio-neuronal tumors may also be identified in patients with chronic 
epilepsy (Table 2; Fig. 5) but show pathognomic histopathological, 
immunohistochemical and molecular features that help to distinguish 
from LeATs addressed by this new ABC terminology proposal
f.c.t.c. follows composite tumor components, t.b.d. to be determined, 
ENET some LeATs that do not express CD34 may still escape clas-
sification within this system (ENET epileptogenic neuroepithelial 
tumor—epileptoma/NOS)
a













 Proposed new A–B–C terminology for LeAT entities
wHO ILAea CD34 MAP2glial MAP2neuronal IDH1
ANeTb ANeTb – +/− Preexisting –
GGc BNeTg + +/− Dysplastic –
DNeTd CNeTd f.c.t.c. f.c.t.c. f.c.t.c. –
DNeTe DNeTe – +/− Floating Neurons –
– eNeTg – +/− +/− t.b.d.
GGc GNeTg – – Dysplastic –
A IIf INeTg – – Preexisting –
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as most prominent histopathological features [25]. These 
tumors should always be devoid of CD34 [10] and IDH1 
immunoreactivity (Fig. 5). MAP2e can be present in the 
neuronal and glial component of DNeTs. Diffuse or non-
specific forms, characterized by a clear cell morphology, 
[13, 21, 22, 41, 89], are not encountered in the proposed 
A–B–C scheme. Such entities will be classified according 
to their CD34 immunoreactivity profile, i.e., most tumors 
with diffuse oligodendroglial-like clear cell components 
will express CD34 and should be encountered into the 
“BNeT” category. Complex forms of DNeTs are already 
recognized by the 2007 wHO classification system, and 
will now be subsumed into the group of composite neu-
roepithelial tumors, “CNeTs”. They are characterized by 
the co-existence of at least two distinct LeAT entities [13, 
67]. Histopathological diagnosis should always include 
specification of tumor variants, i.e., CNeT (DNeT/BNeT) 
(DNeT/GNeT) or any other possible configuration. How-
ever, composite tumors containing semi-malignant compo-
nents, such as PXA [62], should be graded according to the 
highest degree of malignancy, and not classified as CNeT.
The term “ANeT” is synonymous to the angiocentric 
glioma and was introduced into the wHO classification 
system in 2007 [16, 50]. The term “ANeT” and its defini-
tion will remain unchanged, and reserved for those LeATs 
that are characterized by the peculiar growth pattern [47, 
91], and ependymoma-like differentiation displaying intra-
cellular perinuclear eMA-immunopositive dots [68, 91]. 
Up to now, there is no report of CD34 immunoreactivity 
or IDH1 mutations in patients with ANeTs [69], which 
matches with our experience. However, our series of 
ANeTs also comprise tumors with a distinct neuronal com-
ponent as well as variable other cytological morphologies 
[2, 17, 55, 56, 68]. we prefer, therefore, to re-introduce the 
original proposal of Lellouch–Tubiana and describe them 
as “neuroepithelial” tumors rather than pure “gliomas”. 
This proposal will need also further consideration by the 
wHO panel and finally awaits molecular diagnostic confir-
mation [71].
we would like to propose two new A–B–C LeAT enti-
ties. The “INeT” is an isomorphic neuroepithelial tumor 
previously described as isomorphic astrocytoma variant 
corresponding to wHO Grade I, which lacks any CD34 
and glial MAP2 labeling and showed benign long-term 
outcome without recurrence or progression for more than 
13 years [9, 80]. In addition to the initial description of 
six cases in 2004, the eeBB has collected 29 of these ste-
reotypically composed low-grade tumors (Table 2; Fig. 6). 
Their histomorphological characteristic shares a mono-
morphous astroglial appearance with low cellular density. 
Nuclear atypia and mitosis are absent. The tumor matrix 
is fibrillary and reveals intense labeling with antibodies 
directed against GFAP. This tumor can infiltrate adjacent 
cortical and archicortical structures and is usually vis-
ible on MRI as non-contrast enhancing mass lesion with 
homogenous signal increase on T2- and signal decrease on 
T1-weighted images (Fig. 1).
Any other epileptogenic neuroepithelial tumor with 
early seizure onset that does not match the proposed A–B–
C terminology will be provisionally classified as “eNeT—
epileptoma/NOS”. These tumors will most frequently 
share the histomorphological H&e spectrum of BNeT but 
do not express CD34. They also lack other distinguish-
ing histopathological signatures for their classification 
described here as ANeT, DNeT, GNeT or INeT.
The current proposal did not address any criteria of 
atypia or anaplasia as it is meant to start an interdiscipli-
nary discussion about strategies how to better define LeAT 
entities in the near future, i.e., upcoming wHO classifica-
tion systems. Long-term follow-up studies, preferentially 
obtained from prospective observational multi-center tri-
als, will be mandatory to validate the clinical benefits of 
such new definition, i.e., with respect to tumor recurrence, 
malignant progression and postsurgical seizure control. 
These data cannot be retrospectively obtained from our 
eeBB and will need careful reevaluation from submitting 
centers. In addition, large-scale molecular genetic stud-
ies should be carried out to clarify signatures distinguish-
ing A–B–C tumors from any other brain tumor entity. As 
already emphasized, existing literature is not helpful due to 
the inconsistent use of histopathological LeAT terminol-
ogy [88].
Molecular diagnostic findings in LEATs
A promising approach to overcome the difficult distinc-
tion of LeAT variants will be to identify specific molecular 
signatures, which is also helpful to clarify their histogen-
esis and epileptogenicity. Several recent studies have been 
performed and will be briefly summarized. However, the 
distinction between GG and DNT was often not used with 
same or comparable definitions and terminology (as dis-
cussed above) and all data will be summarized, therefore, 
as LeAT instead of what have been published to represent 
specific GG or DNT characteristics.
Analysis of chromosomal copy number alterations 
(CNAs) in a cohort of 61 patients with LeAT (specified as 
GG without reference to CD34) revealed gains of chromo-
somes 7 and 5 as common aberrations, the last being more 
frequent in LeAT compared to astrocytomas wHO grade 
II [40]. More recently, copy number profiling of a large 
cohort of 131 LeAT confirmed the occurrence of gains 
of chromosomes 5 and 7 in both GG and DNT subtypes, 
detecting different patterns of chromosomal alterations, 
including also somatic intra- and/or interchromosomal 
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chromothripsis (Prawabo et al. personal communication). 
These observations suggest that LeATs share similar 
molecular features despite their large spectrum of mor-
phological variants. However, this conclusion needs to be 
confirmed using any new proposal for tumor terminology. 
Loss of heterozygosity (LOH) of chromosomal arms 1p 
and 19q has been repetitively recognized and confirmed as 
molecular hallmarks in oligodendrogliomas [74], but rarely 
reported in LeATs [30, 65, 88], representing an additional 
diagnostic feature in cases in which the small size of the 
biopsy raises differential diagnosis of oligodendrogliomas. 
we also strongly recommend the evaluation of IDH1 and 
IDH2 gene mutations as useful tool for the differential 
diagnosis between wHO I° LeAT and wHO II° gliomas. 
IDH1 mutations can be recognized using a mutation-spe-
cific antibody directed against the most common mutation 
site in wHO II° gliomas [3, 18, 19, 37, 44], but generally 
absent in LeAT [15, 30, 46, 65, 88].
The combined molecular analysis of IDH1/IDH2 and 
BRAF mutations may represent the most powerful diagnos-
tic tool in the evaluation of LeAT. A mutation of the BRAF 
oncogene (v600e mutation) has been recently shown in 
different entities within the LeAT spectrum, including 
“GG”, “desmoplastic infantile gangliogliomas” and “DNT” 
[20, 24, 30, 45, 65, 79, 97]. The presence of BRAF v600e 
mutations can be evaluated by direct DNA sequencing and 
by BRAF v600e immunohistochemical detection. How-
ever, the low cellularity of these tumors and the frequent 
admixture of normal cell components may produce false-
negative findings. Accordingly, immunohistochemical stud-
ies emphasize the importance of performing DNA sequenc-
ing from macrodissected tissue, or even to apply single-cell 
laser-capture microdissection [45, 65]. The identification of 
mechanisms underlying tumor development in BRAF wild-
type LeAT cases represents a major challenge for future 
studies, which also requires a reliable terminology and his-
topathological classification of these tumor entities. Inter-
estingly, evaluation of BRAF mutation in a large cohort of 
both pediatric and adult LeAT reveals a positive correlation 
with the oncofetal marker protein CD34 [65]. These stud-
ies also support the pathogenic role of BRAF in low-grade 
glial tumors arising in young age groups and including 
entities, such as pilocytic astrocytomas and pleomorphic 
xanthoastrocytoma [32, 79]. A remaining issue is repre-
sented by the possible prognostic value of the BRAF status 
on recurrence-free survival [24] and postoperative seizure 
outcome [65], which will also require further evaluation.
The search for additional mechanisms involved in LeAT 
development and epileptogenicity has identified the mTOR 
signaling pathway as promising candidate [49]. The mTOR 
pathway acts as key regulator of cell size and growth con-
trol, proliferation, differentiation and survival during brain 
development, and increasing evidence supports the role of 
the TOR pathway in a wide variety of neurological disor-
ders including both MCD and brain tumors [1, 23, 26, 96]. 
enhanced mTOR pathway activation has been reported in 
LeAT, such as GG and DNT [4, 14, 65, 78], suggesting 
a pathogenic link between these tumor entities and focal 
MCD, such as FCD ILAe Type IIb and cortical tubers in 
tuberous sclerosis complex (TSC), [23, 49]. Mutational 
analysis of TSC1 and TSC2 has been performed in LeAT, 
but failed to identify mutations [59]. A somatic mutation 
was reported in intron 32 of the TSC2 gene in glial cells of 
one LeAT patient, but not in dysplastic neurons [5]. Thus, 
additional efforts are necessary to clarify the mechanism 
underlying the deregulation of mTOR in LeAT.
Understanding the mechanisms that underlie epilep-
togenesis in LeAT is essential to develop effective treat-
ment in young patients in which drug-resistant epilepsy 
critically affects their daily life. Over the last decades, 
several hypotheses have been put forward to explain epi-
leptogenesis in LeAT patients. These studies suggested the 
involvement of both tumor-related factors (i.e., tumor size, 
tumor location, cellular composition), as well as of peritu-
moral changes (i.e., hypoxia and acidosis, ionic and enzy-
matic changes, deposition of hemosiderin; [27, 70, 90]). 
A better definition of the molecular biology of LeAT may 
not only aid the development of a more targeted treatment 
involving specific pathogenic pathways, but may also con-
tribute to explain the epileptogenic nature of specific LeAT 
entities, such as GG (i.e., BNeT, GNeT) and DNT.
The road to epilepsy surgery in patients with brain 
tumors
Clinical management of patients with epilepsy due to brain 
tumors exemplifies an important area of conflict between 
medical specialities, i.e., neurooncology and epileptol-
ogy [48]. As a matter of fact, many brain tumors manifest 
with seizures and will not require attention by specialized 
epileptologists. Patients showing clinical symptoms for 
increased intracranial pressure with/without seizures will 
have brain imaging to localize a suspected brain tumor. 
Most centers will then move forward to neurosurgical 
resection to reduce mass effects and to obtain a written 
histopathological report guiding further treatment options. 
This applies for most adult or elderly patients suffering 
from rapid tumor growth in cortical or subcortical areas. 
But we need to consider the red flags, which require a dif-
ferent approach and careful neurophysiological attention. 
As prominent example, children or adolescents with a brain 
tumor manifesting in the temporal lobe should be carefully 
examined, as these neoplasms usually belong to the spec-
trum of LeAT and not to semi-malignant or malignant glio-
mas. The benign nature of most LeATs and their slow cell 
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growth will not require surgical treatment or any adjuvant 
radiation or chemotherapy [75]. Instead, control of spon-
taneous seizures should be the primary treatment target 
to reduce the risk for progressive cognitive impairment or 
adverse effects of medication. This can be exemplified by 
a mean disease onset of LeATs at 16.5 years (Table 1) and 
temporal lobe location in 80 % of our LeAT series. These 
patients should be consulted by a comprehensive and multi-
disciplinary epilepsy center. Specialized expertise in read-
ing neuroradiology images may already help to clarify the 
underlying nature of a given LeAT (Figs. 1, 2). If medical 
treatment does not achieve sustained seizure control [63], 
surgical resection should be recommended as primary and 
in many instances also curative treatment option, although 
a controlled and randomized clinical trial was performed 
so far only for surgical treatment of drug-resistant tempo-
ral lobe epilepsy [92]. If epilepsy surgery is considered in 
patients suffering from brain tumors, we have to anticipate 
two distinct clinical scenarios: (1) Tumor is located in non-
dominant and non-eloquent cortical and subcortical areas. 
we do not need invasive monitoring in this situation. A 
generous resection involving the tumoral area plus adjacent 
cortex can be performed, guided by intraoperative electro-
corticography (eCoG) if available. (2) Tumor is located in 
or in close proximity to eloquent cortical and subcortical 
areas. As discussed above, the MRI-identified tumor may 
or may not be intrinsically epileptogenic and perilesional 
cortex may also contribute to the generation and early 
propagation of the epileptic seizures. In this clinical sce-
nario where there is an anatomical proximity with func-
tional areas in the brain, such as a dominant hippocampus, 
Brocca’s speech or prefrontal motor areas, the anatomical 
boundaries between the epileptogenic zone, the tumoral 
area and functional cortical and subcortical areas can be 
very poorly defined if based only on non-invasive data. In 
this particular situation, invasive monitoring is strongly 
recommended.
There is, however, no agreement regarding optimal sur-
gical strategies, and studies comparing lesionectomy with 
more extensive resection of the presumed peritumoral epi-
leptogenic zone are lacking. Using not only a tumoral, but 
also an epilepsy surgery-oriented strategy, LeAT-associated 
epilepsies usually have excellent seizure outcome follow-
ing appropriate surgical resection. Timing of surgical treat-
ment is debatable in patients whose seizures are well con-
trolled. when perceived benefits of surgical intervention 
are thought to overweigh any surgical or neurological risks, 
surgery can be offered early. In the decision making, one 
should also take into account the rare risk of tumor growth 
and malignant transformation, the real risk of later develop-
ment of pharmaco-resistance, the potential side effects of 
long-term treatment with antiepileptic medications and the 
favorable outcome of surgical intervention, which of course 
depends on the location of the LeAT and its proximity to 
essential eloquent cortex.
The predilection of LeATs to involve the temporal lobe 
(and in particular the anterior, basal and mesial compart-
ments of the temporal lobe) has direct implications in the 
presurgical evaluation and tailored surgical therapy, which 
may or may not include the hippocampus in the area of 
resection. LeATs involving or abutting the mesial temporal 
structures are usually associated with a more widespread 
epileptogenic network and should be regarded as a distinct 
electroclinical group. Moreover, LeATs can be associated 
with focal cortical dysplasia ILAe Type IIIb and, there-
fore, a “curative” lesionectomy has to be extended beyond 
the MRI-identifiable lesion. Tumor recurrence and malig-
nant transformation are rather unusual, but should never 
be excluded, especially when dealing with certain histo-
pathological subtypes [4]. In these instances, the focus of 
the neurology and oncology team is to not only limit tumor 
growth but also eliminate seizures, which can significantly 
impair quality of life. One cannot overemphasize the 
importance of appropriate surveillance plans following suc-
cessful resection of such tumors. Lastly, controlled studies 
are needed to examine when it is appropriate to discontinue 
AeDs in patients with sustained seizure-freedom following 
surgical resection.
In conclusion, this review and our proposal of the 
A–B–C terminology are meant to initiate an interdiscipli-
nary consensus discussion between neuropathologists, neu-
rooncologists, epileptologists and any other medical and 
research discipline toward a better understanding of each 
tumors biologic behavior and successful medical treatment 
in patients suffering from drug-resistant focal epilepsy.
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